Ingo Alberti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ingo Alberti has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Yogeshvar N. Kalia
University of Geneva
10 shared publications - Richard H. Guy
University of Bath, Department of Life Sciences, Claverton Down, Bath BA2 7AY, UK
7 shared publications Aarti Naik
University of Geneva
6 shared publicationsCatherine Curdy
Centre Interuniversitaire de Recherche et d'Enseignement, Universités de Genève et Lyon, Pharmapeptides, Parc d'Affaires International, F-74166 Archamps, France
2 shared publicationsJean-Daniel Bonny
Novartis Pharma AG, CH-4002 Basel, Switzerland
2 shared publicationsYong Chen
School of Pharmaceutical Sciences, University of Geneva & University of Lausanne, 30 Quai Ernest Ansermet, 1211 Geneva, Switzerland
2 shared publications
Latest Publications
- 1 February 2016
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 99, 103-113
Topical iontophoretic delivery of ionizable, biolabile aciclovir prodrugs: A rational approach to improve cutaneous bioavailability
- 1 February 2016
- Published by Elsevier in European Journal of Pharmaceutics and Biopharmaceutics
- Vol. 99, 103-113
Topical iontophoretic delivery of ionizable, biolabile aciclovir prodrugs: A rational approach to improve cutaneous bioavailability
- 1 December 2013
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 50 (5) , 609-622
Next generation intra- and transdermal therapeutic systems: Using non- and minimally-invasive technologies to increase drug delivery into and across the skin
- 1 December 2013
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 50 (5) , 609-622
Next generation intra- and transdermal therapeutic systems: Using non- and minimally-invasive technologies to increase drug delivery into and across the skin
- Open Access
- 6 November 2007
- Published by Springer Nature in Pharmaceutical Research
- Vol. 25 (1) , 87-103
In Vivo Methods for the Assessment of Topical Drug Bioavailability
This paper reviews some current methods for the in vivo assessment of local cutaneous bioavailability in humans after topical drug application. After an introduction discussing the importance of local drug bioavailability assessment and the limitations of model-based predictions, the focus turns to the relevance of experimental studies. The available techniques are then reviewed in detail, with particular emphasis on the tape stripping and microdialysis methodologies. Other less developed techniques, including the skin biopsy, suction blister, follicle removal and confocal Raman spectroscopy techniques are also described.
- 6 November 2007
- Published by Springer Nature in Pharmaceutical Research
- Vol. 25 (1) , 87-103
Open AccessIn Vivo Methods for the Assessment of Topical Drug Bioavailability
This paper reviews some current methods for the in vivo assessment of local cutaneous bioavailability in humans after topical drug application. After an introduction discussing the importance of local drug bioavailability assessment and the limitations of model-based predictions, the focus turns to the relevance of experimental studies. The available techniques are then reviewed in detail, with particular emphasis on the tape stripping and microdialysis methodologies. Other less developed techniques, including the skin biopsy, suction blister, follicle removal and confocal Raman spectroscopy techniques are also described.
- 16 September 2005
- Published by Informa Healthcare in Expert Opinion on Drug Delivery
- Vol. 2 (5) , 935-950
Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery
Transdermal gels are designed to deliver sustained drug amounts, resulting in systemically consistent levels. They represent an improvement compared with transdermal delivery by patches because they offer more dosage flexibility, less irritation potential and a better cosmetic appearance. Advanced Transdermal Delivery™ (ATD™) gel technology was developed in order to provide enhanced passive skin permeation of various active drugs for the treatment of many conditions, including hypogonadism, female sexual dysfunction, postmenopausal symptoms, overactive bladder and anxiety. The technology consists of a combination of solvent systems and permeation enhancers enabling systemic drug delivery, and is covered by many patents. Pharmaceutical development of formulations based on the technology allowed optimisation of physicochemical parameters (rheological profile, pH) as well as skin permeation properties (type and concentration of permeation enhancers, thermodynamic activity of the drug). This gel technology ha...
- 16 September 2005
- Published by Informa Healthcare in Expert Opinion on Drug Delivery
- Vol. 2 (5) , 935-950
Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery
Transdermal gels are designed to deliver sustained drug amounts, resulting in systemically consistent levels. They represent an improvement compared with transdermal delivery by patches because they offer more dosage flexibility, less irritation potential and a better cosmetic appearance. Advanced Transdermal Delivery™ (ATD™) gel technology was developed in order to provide enhanced passive skin permeation of various active drugs for the treatment of many conditions, including hypogonadism, female sexual dysfunction, postmenopausal symptoms, overactive bladder and anxiety. The technology consists of a combination of solvent systems and permeation enhancers enabling systemic drug delivery, and is covered by many patents. Pharmaceutical development of formulations based on the technology allowed optimisation of physicochemical parameters (rheological profile, pH) as well as skin permeation properties (type and concentration of permeation enhancers, thermodynamic activity of the drug). This gel technology ha...
- 1 March 2004
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 271 (1-2) , 251-256
Non-invasive assessment of the effect of formulation excipients on stratum corneum barrier function in vivo
- 1 March 2004
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 271 (1-2) , 251-256
Non-invasive assessment of the effect of formulation excipients on stratum corneum barrier function in vivo
- 1 October 2001
- Published by Springer Nature in Pharmaceutical Research
- Vol. 18 (10) , 1472-1475
Assessment and Prediction of the Cutaneous Bioavailability of Topical Terbinafine, In Vivo, in Man
- 1 October 2001
- Published by Springer Nature in Pharmaceutical Research
- Vol. 18 (10) , 1472-1475
Assessment and Prediction of the Cutaneous Bioavailability of Topical Terbinafine, In Vivo, in Man
- 1 August 2001
- Published by S. Karger AG in Skin Pharmacology and Physiology
- Vol. 14 (Suppl. 1) , 82-86
Assessment of Topical Bioavailability in vivo: The Importance of Stratum corneum Thickness
We present a method to determine the cutaneous bioavailability and hence to evaluate the bioequivalence of topically applied drugs in vivo. The procedure uses serial tape-stripping and transepidermal water loss measurements to quantify the thickness of the removed stratum corneum (SC) and to determine the intact membrane thickness. Following tape-stripping, the drug is extracted from the tapes and assayed, e.g., by HPLC. This provides a drug concentration profile as a function of the normalized position within the SC. The data are fitted to a solution of Fick’s second law of diffusion in order to calculate characteristic membrane transport parameters. Integration of the concentration profile over the entire SC thickness, that is, the ‘area-under-the-curve’, provides a measure of the cutaneous bioavailability and hence can be used to assess the bioequivalence of topically applied drugs.
- 1 August 2001
- Published by S. Karger AG in Skin Pharmacology and Physiology
- Vol. 14 (Suppl. 1) , 82-86
Assessment of Topical Bioavailability in vivo: The Importance of Stratum corneum Thickness
We present a method to determine the cutaneous bioavailability and hence to evaluate the bioequivalence of topically applied drugs in vivo. The procedure uses serial tape-stripping and transepidermal water loss measurements to quantify the thickness of the removed stratum corneum (SC) and to determine the intact membrane thickness. Following tape-stripping, the drug is extracted from the tapes and assayed, e.g., by HPLC. This provides a drug concentration profile as a function of the normalized position within the SC. The data are fitted to a solution of Fick’s second law of diffusion in order to calculate characteristic membrane transport parameters. Integration of the concentration profile over the entire SC thickness, that is, the ‘area-under-the-curve’, provides a measure of the cutaneous bioavailability and hence can be used to assess the bioequivalence of topically applied drugs.
- 1 May 2001
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 219 (1-2) , 11-19
Effect of ethanol and isopropyl myristate on the availability of topical terbinafine in human stratum corneum, in vivo
- 1 May 2001
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 219 (1-2) , 11-19
Effect of ethanol and isopropyl myristate on the availability of topical terbinafine in human stratum corneum, in vivo
- 1 April 2001
- Published by Elsevier in Journal of Controlled Release
- Vol. 71 (3) , 319-327
In vivo assessment of enhanced topical delivery of terbinafine to human stratum corneum
- 1 April 2001
- Published by Elsevier in Journal of Controlled Release
- Vol. 71 (3) , 319-327
In vivo assessment of enhanced topical delivery of terbinafine to human stratum corneum